2600795-07-9
2600795-07-9
Chemical Structure
M4K-2009
- CAS No.: 2600795-07-9
- Formula:C25H29N3O3
- Molecular Weight:419.52
InChIKey: RKBYYWVZFBATHQ-UHFFFAOYSA-N
SMILES: COC(C=C1C2=CN=CC(C3=CC=C(N4CCNCC4)C=C3)=C2C)=C(C(OC)=C1)OC
Biological Activity: M4K-2009 is an orally bioactive ALK2 inhibitor with an IC50 of 13 nM. M4K-2009 exerts comparable inhibitory potency against wild-type and mutant ALK2G328V, ALK2R206H, and ALK2R258G. M4K-2009 exhibits moderate off-target inhibitory activity against hERG potassium channels. M4K-2009 can be used in studies related to diffuse intrinsic pontine glioma[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
M4K-2009 | 99.35% | M4K-2009 is an orally bioactive ALK2 inhibitor with an IC50 of 13 nM. M4K-2009 exerts comparable inhibitory potency against wild-type and mutant ALK2G328V, ALK2R206H, and ALK2R258G. M4K-2009 exhibits moderate off-target inhibitory activity against hERG potassium channels. M4K-2009 can be used in studies related to diffuse intrinsic pontine glioma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Smil D, et al. Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma. J Med Chem. 2020;63(17):10061-10085. [Content Brief]
- [2]. Ensan D, et al. Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma. J Med Chem. 2020;63(9):4978-4996. [Content Brief]
- [3]. González-Álvarez H, et al. Discovery of Conformationally Constrained ALK2 Inhibitors. J Med Chem. 2024;67(6):4707-4725. [Content Brief]
Keywords
